Generex Biotechnology Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Generex Biotechnology Corporation
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.
Takeda has linked up with COVID-19 vaccine frontrunner Novavax, while Daiichi Sankyo has been selected by Japan’s Ministry of Health, Labour and Welfare as an official participant under the first round of a national government initiative to build production capacity.
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products – they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen..
- Medical Devices
- Large Molecule
- Other Names / Subsidiaries
- Antigen Express, Inc.
- Grainland Pharmacy LLC
- Hema Diagnostic Systems, LLC
- Medisource Partners
- NuGenerex Distribution Solutions, LLC
- NuGenerex Immuno-Oncology
- Pantheon Medical
- Pantheon Medical – Foot & Ankle
- Regentys Corporation
- Veneto Holdings, LLC